Despite the numerous studies on the effects of HDACi on genomic integrity, and their interactions with poly(ADP ribose) polymerase (PARP) inhibitors (PARPi) in solid tumors [15–19], analysis of their direct effects on protein poly(ADP-ribosyl)ation (PARylation), which is critical for DNA repair, warrants a more thorough study in hematologic cancers. The gene discussed is PARP1; the disease is hematopoietic and lymphoid cell neoplasm.